AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29676139
Drug: Xinling Wan
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinling Wan (two pills each time, three times daily for 4 weeks)
Trial: 16556147
Drug: Steroid maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid maintenance
Trial: 15284215
Drug: Immunosuppressive/antibiotic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive/antibiotic treatment (IA)
Trial: 11331055
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n = 1,380)
Trial: 2447789
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (2 g.kg‐1.day‐1)
Trial: 2447789
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.55 g.kg‐1.day‐1)
Trial: 27418820
Drug: IB/SAL-HFA pMDI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IB/SAL-HFA pMDI, 20 μg qid
Trial: 27418820
Drug: IB/SAL-CFC pMDI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IB/SAL-CFC pMDI, 20 μg qid
Trial: 26037428
Drug: Pasireotide 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 900 μg subcutaneously twice daily for 7 days
Trial: 22862906
Drug: Recapture Life
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recapture Life intervention (six, weekly, 90-minute online group sessions led by a psychologist)
Trial: 18989993
Drug: One 800
RxNorm normalized name: metaxalone 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 800 mg tablet (reference)
Trial: 18989993
Drug: Two 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 400 mg tablets (test)
Trial: 18989993
Drug: One 800
RxNorm normalized name: metaxalone 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 800 mg tablet in fed conditions (test)
Trial: 18989993
Drug: One 800
RxNorm normalized name: metaxalone 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 800 mg tablet in fasting conditions (reference)
Trial: 16433404
Drug: 14% doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14% doxycycline gel (DOXY)
Trial: 12598265
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion of levobupivacaine 0.5%, 3 mL/h (n = 33)
Trial: 12598265
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion of levobupivacaine 0.15%, 10 mL/h (n = 27)
Trial: 8295811
Drug: Clarithromycin oral
RxNorm normalized name: clarithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin oral suspension (7.5 mg/kg, max 500 mg, twice daily)
Trial: 8295811
Drug: Cefadroxil oral
RxNorm normalized name: cefadroxil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil oral suspension (15 mg/kg, max 1000 mg, twice daily)
Trial: 8295811
Drug: Clarithromycin oral
RxNorm normalized name: clarithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin oral suspension
Trial: 8295811
Drug: Cefadroxil oral
RxNorm normalized name: cefadroxil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil oral suspension
Trial: 3552504
Drug: Oral colonic
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral colonic lavage solution containing sodium sulfate and polyethylene glycol
Trial: 26232542
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine (two doses, 1-month apart)
Trial: 21334621
Drug: Antichlamydial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antichlamydial treatment
Trial: 21334621
Drug: No antichlamydial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antichlamydial treatment
Trial: 17239430
Drug: Weekly topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly topotecan 4.0 mg/m2 on days 1, 8, and 15 of a 28-day cycle
Trial: 11379679
Drug: Intravenous 30
RxNorm normalized name: fat emulsion, intravenous 30% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 30 mg ketorolac administered before tourniquet inflation
Trial: 11379679
Drug: Intravenous 30
RxNorm normalized name: fat emulsion, intravenous 30% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 30 mg ketorolac administered after tourniquet inflation
Trial: 7833219
Drug: L-NG-monomethyl-arginine (L-NMMA)
RxNorm normalized name: L-Ng-monomethyl Arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NG-monomethyl-arginine (L-NMMA) 4 mumol min-1 for 5 min
Trial: 7833219
Drug: Bradykinin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin 10 and 100 pmol min-1 for 3 min each dose
Trial: 7833219
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN) 2 and 5 nmol min-1 for 3 min each dose
Trial: 19628666
Drug: Bradykinin B(2)
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin B(2) receptor blocker HOE‐140
Trial: 8845473
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (EP) at 100 mg/m2/day for 5 days
Trial: 8845473
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (EP) at 75 mg/m2/day for 5 days
Trial: 8845473
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (EP) at 50 or 75 mg/m2/day for 5 days
Trial: 25850865
Drug: Tight glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycemic control with insulin (insulin titrated to maintain blood glucose between 80 and 110 mg/dL)
Trial: 22192068
Drug: myo-inositol 2
RxNorm normalized name: myo-Inositol 2-dehydrogenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: myo-inositol 2 g b.i.d. (n = 40)
Trial: 22192068
Drug: myo-inositol 2
RxNorm normalized name: myo-Inositol 2-dehydrogenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: myo-inositol 2 g b.i.d.
Trial: 15660059
Drug: Intravenous, intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous, intraoperative unfractionated heparin
Trial: 15660059
Drug: Intravenous, intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous, intraoperative saline (Control)
Trial: 11877611
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (dalteparin: 2,500 IU for ≤70 kg and 5,000 IU for >70 kg, started perioperatively and given once daily for 4 weeks)
Trial: 8701511
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 50 mcg (b.i.d.)
Trial: 8701511
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol controlled release 8 mg (b.i.d.)
Trial: 18709511
Drug: Esomeprazole (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20-40 mg daily)
Trial: 25692384
Drug: Topical rapamycin
RxNorm normalized name: natamycin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rapamycin gel, 0.2%, applied twice a day for 12 weeks
Trial: 25692384
Drug: Topical rapamycin
RxNorm normalized name: natamycin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rapamycin treatment
Trial: 23434908
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (12 mg of lutein and 280 mg of DHA daily)
Trial: 19681943
Drug: TiO(2) thin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TiO(2) thin film modified implants
Trial: 16696748
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention including occupational and physical therapy sessions, home modifications, problem-solving strategies, energy conservation, safe performance techniques, fall recovery techniques, balance and muscle strength training.
Trial: 1564023
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate (MPH)
Trial: 1564023
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of standard and sustained-release MPH
Trial: 29544062
Drug: CHO drink
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO drink (75 g CHO)
Trial: 29544062
Drug: CHO+PRO drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO+PRO drink (60.5 g CHO and 14.5 g PRO)
Trial: 22571514
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control with release time
Trial: 22571514
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control with routine duties
Trial: 18953465
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of saccharides
Trial: 11379469
Drug: Modified short-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified short-course chemotherapy (S: streptomycin, H: isoniazid, R: Rifampicin, Z: pyrazinamide) for 2 months followed by 6 months of thiacetazone and isoniazid (2SHRZ/6TH or 2EHRZ/6TH)
Trial: 2899509
Drug: xamoterol 200
RxNorm normalized name: xamoterol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol 200 mg twice daily
Trial: 1675867
Drug: enalapril 2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 2.5, 5 or 10 mg twice daily
Trial: 1675867
Drug: xamoteril 200
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoteril 200 mg twice daily
Trial: 24750799
Drug: Guna‐Interleukin 4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guna‐Interleukin 4, Guna‐Interleukin 10, and Guna‐Interleukin 11 at the concentration of 10 fg/ml
Trial: 12917745
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements for 12 months
Trial: 12917745
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nutritional supplements)
Trial: 10919170
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (30 g alcohol/day)
Trial: 10919170
Drug: Alcoholic solution
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic solution (same degree of alcohol)
Trial: 8737133
Drug: Sparfloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily)
Trial: 8737133
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg orally twice daily for 10 to 14 days)
Trial: 1570375
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg amitriptylinoxide (AT‐NO) IV
Trial: 1570375
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg amitriptylinoxide (AT‐NO) orally
Trial: 1570375
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg amitriptyline (AT) IV
Trial: 1570375
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with AT‐NO
Trial: 1570375
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with AT
Trial: 16210665
Drug: 2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d of fish oil
Trial: 16210665
Drug: 2 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/d of soy oil
Trial: 12358655
Drug: Ondansetron 0.1
RxNorm normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.1 mg x kg(‐1)
Trial: 12358655
Drug: Droperidol 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.01 mg.kg‐1
Trial: 1557928
Drug: Monocomponent pertussis
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monocomponent pertussis toxoid vaccine
Trial: 9690722
Drug: famotidine 10
RxNorm normalized name: famotidine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 10 mg
Trial: 7590425
Drug: cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 200 mg
Trial: 7590425
Drug: cimetidine 100
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 100 mg
Trial: 6893378
Drug: Cimetidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (0.3 mg/kg i.v. bolus)
Trial: 6893378
Drug: Secretin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secretin (3 CU/kg/h i.v. infusion)
Trial: 6137116
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cimetidine and pirenzepine
Trial: 29105631
Drug: Cosmetic cream
RxNorm normalized name: POLYGONUM CUSPIDATUM LEAF 0.05 g in 50 g / CENTELLA ASIATICA LEAF 0.05 g in 50 g / RETINOL 0.05 g in 50 g / CERAMIDE NP 0.05 g in 50 g / ROSMARINUS OFFICINALIS FLOWER 0.05 g in 50 g TOPICAL CREAM [BARUBT A313 Cosmetic Cream With Retinyl Palmitate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosmetic cream containing 4% Saussurea lappa extract
Trial: 19948613
Drug: Oral 25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25% dextrose treatment, given 2 minutes before the injection
Trial: 19948613
Drug: Skin-to-skin contact,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-to-skin contact, initiated 2 minutes before the injection and persisting throughout the procedure
Trial: 19948613
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral 25% dextrose treatment and skin-to-skin contact
Trial: 15035552
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (Utrogestan, Besins International) 400 mg starting on the day of oocyte retrieval (Group A)
Trial: 15035552
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (Utrogestan, Besins International) 400 mg starting on the day of embryo transfer (Group B)
Trial: 2783702
Drug: Fluoxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (up to 40 mg/day)
Trial: 9569795
Drug: Piroxicam FDDF
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam FDDF 40 mg
Trial: 8371917
Drug: PhXA41 (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhXA41 (35 micrograms/ml)
Trial: 8371917
Drug: PhXA41 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhXA41 (60 micrograms/ml)
Trial: 8371917
Drug: PhXA41 (115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhXA41 (115 micrograms/ml)
Trial: 3524514
Drug: RS-86 (muscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS-86 (muscarinic agonist) administered orally at maximum individually tolerated dose levels for eight days
Trial: 29505772
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg every 6 hours
Trial: 29505772
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg every 6 hours
Trial: 24420746
Drug: efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz 600 mg/day
Trial: 24420746
Drug: efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz 600 mg with rifampin 600 mg/day
Trial: 20934562
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone replacement therapy (non-HRT)
Trial: 15199033
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser treatment (fluence of 3 J/cm2)
Trial: 9012902
Drug: Helium/oxygen (He/O2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helium/oxygen (He/O2) inhalation for 90 minutes
Trial: 28663621
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (0.3 mg)
Trial: 26557673
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with antioxidants/omega 3 fatty acids (A/ω3) for three months
Trial: 23301559
Drug: Benzocaine mucoadhesive
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzocaine mucoadhesive patches (20%)
Trial: 18450232
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of ondansetron intravenously 30 minutes prior to completion of the surgery
Trial: 18450232
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of ondansetron intravenously prior to the induction of anesthesia
Trial: 17557432
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of pseudoephedrine sulfate and 10 mg of domperidone at bedtime for 30 days (open-label trial)
Trial: 17557432
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of pseudoephedrine sulfate plus 10 mg of domperidone (placebo-controlled trial)
Trial: 17557432
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of pseudoephedrine sulfate plus 10 mg of domperidone (placebo-controlled trial)
Trial: 17557432
Drug: Drug combination
RxNorm normalized name: Other anti-dementia drug combinations in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug combination (pseudoephedrine sulfate and domperidone)
Trial: 15058039
Drug: antibiotics only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotics only
Trial: 10716106
Drug: Closed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed treatment (77 patients)
Trial: 10716106
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment (65 patients)
Trial: 9360163
Drug: WBHT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBHT in patients on protease inhibitor/triple drug therapy
Trial: 1550466
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg/d and 20 mg/d
Trial: 3898350
Drug: Cimetidine maintenance
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine maintenance therapy
Trial: 27528611
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL hyaluronic acid (HA) injection at the end of arthroscopic meniscectomy
Trial: 23924070
Drug: KOH 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOH 10% solution applied two times a day until lesions disappeared
Trial: 23924070
Drug: Cryotherapy performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy performed with liquid nitrogen spray, repeated weekly for 4 weeks
Trial: 20196969
Drug: 0.9 g
RxNorm normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g of n-3 polyunsaturated fatty acids (n-3 PUFA) daily for 24 weeks
Trial: 15242867
Drug: Algorithm guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm guided by oesophageal Doppler flowmetry to maintain a stroke index above 35 ml/m2
Trial: 9676822
Drug: m-CPP (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-CPP (0.08 mg/kg i.v.) + placebo
Trial: 9676822
Drug: m-CPP (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-CPP (0.08 mg/kg i.v.) + ondansetron (0.15 mg/kg i.v.)
Trial: 9676822
Drug: ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (0.15 mg/kg i.v.) + placebo